Angiex Private Investor Briefing - Virtual
Dear Investors,
For oncology investors, some of the most compelling opportunities emerge when a company moves from clinical hypothesis to clinical proof.
Angiex is advancing AGX101, a Phase 1 antibody-drug conjugate (ADC) designed to target both tumor-associated blood vessels and TM4SF1-expressing tumor cells. With clinical data emerging and several key development milestones ahead, the company is approaching an important stage in its clinical program.
Company Overview
Angiex is a clinical-stage oncology company developing targeted therapies for solid tumors. Its lead program, AGX101, is designed to deliver a maytansinoid payload to both tumor-associated endothelial cells and TM4SF1-expressing tumor cells. The program is currently in Phase 1, with data from 36 patients and ongoing evaluation of safety, dose optimization, and exploratory efficacy.
Why Investors Are Taking Notice
Clinical Data Emerging — Early observations include reduced metabolic activity on PET, imaging changes consistent with devascularization, and stable disease in select patients.
Near-Term Milestones — Angiex is working toward RP2D selection, additional clinical data, and proof-of-concept milestones.
Broad Development Potential — TM4SF1 expression supports evaluation across multiple solid tumor indications, subject to clinical validation.
Current Financing — Angiex is raising a $10M top-off financing to support the next phase of clinical development.
Join us September 22 for a virtual investor briefing with the Angiex team to learn more about AGX101, the clinical data emerging to date, upcoming milestones, and the current investment opportunity.
Event Details:
Date: September 22
Time: 11:30 am - 12:30 pm ET
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Skylar Rallison at srallison@opus8.com.
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
twong@opus8.com